Synthorx fortifies $63m series C

May 1, 2018 •

Synthorx's artificial genetic DNA pairings are expected to support the administration of an immuno-oncology drug previously hindered by safety issues.

Synthorx, a US-based immuno-oncology drug developer spun out from Scripps Research Institute, closed a $63m series C round yesterday that included spinout-focused investment firm Osage University Partners.
Healthcare-focused investment firm OrbiMed led the round, which also featured Avalon Ventures, RA Capital Management and Correlation Ventures.
Synthorx is exploiting new genetic DNA pairings to enhance the formulation of interleukin-2 (IL-2), a drug currently hindered by safety concerns which could otherwise complement immuno-oncology treatments such as checkpoint inhibitors.
The…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

Can University of Kentucky researchers bring new flavours to whisky?

The University of Kentucky has formed an industry-university partnership to advance aspects such as sustainable agriculture in the whiskey distilling industry.

Make sure UK proof-of-concept funds go beyond Golden Triangle, say experts

The £40m recently allocated by the UK government to proving university research is commercially viable shouldn't just benefit Oxford, Cambridge and London say sector pundits.

Databricks cofounder launches $150m spinout fund with UC Berkeley focus

The investment fund will mostly back founders from the US university.

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.